Sarepta Therapeutics SRPT
NASDAQ SRPT
$22.50 -0.49 (-2.13%)
As of: Sep 4, 2026 · 3:59 PM EDT

Sarepta Therapeutics (SRPT) Construction in Progress (2013)

Sarepta Therapeutics (SRPT) posted quarterly Construction in Progress of $11.3 million for Q4 2013.

Analysis

Sarepta Therapeutics (SRPT) Construction in Progress (2013) Analysis & Trends

Sarepta Therapeutics' Construction in Progress history runs 1 years deep, the most recent figure standing at $11.3 million for Q4 2013.

  • In Q4 2013, Construction in Progress changed N/A year-over-year to $11.3 million; the TTM figure through Dec 2013 stood at $11.3 million (changed N/A YoY), while the FY2013 annual figure was $11.3 million, changed N/A from the prior year.
  • Construction in Progress for Q4 2013 stood at $11.3 million.
  • The five-year high for Construction in Progress was $11.3 million in Q4 2013, with the low at $11.3 million in Q4 2013.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Construction in Progress (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 152.67 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Sarepta Therapeutics 2.36 Bn 1.57 Bn 251.87 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2013 11.30 Mn